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LETTER TO THE EDITOR 
Dear Sir. 
In vitro and in vivo activation of CD4' lymphocytes by autologous tumor cells 
During the last 10 years, attempts have been made to isolate tumor-specific lymphocytes. Thus far, most of the so-called 
tumor-specific cytotoxic T-lymphocyte (CTL) responses observed were directed against melanoma cells (Anichini et al., 1987; 
Hersey and Bolhuis, 1987). Only occasionally were such responses observed against larynx and bladder carcinoma (Cozzolino 
et al., 1987) or ovarian carcinoma (Ferrini et al., 1985). For most types of spontaneous tumor it remains uncertain whether they 
are able to provoke an immune response. Various causes may underlie low anti-tumor responses. First, the host may be 
immunodeficient (Wheelock et al., 1983). Second, the tumor cells may induce immunosuppressive mechanisms, such as lowering 
or abrogation of the activity of tumor-directed CTL (Mukherji et al., 1986). Third, tumor cells can be non-immunogenic when 
they lack expression of major histocompatibility complex (MHC) or tumor-specijic or -associated antigens (Barlett, 1972). 
Various lymphocyte sources, activation protocols and cloning strategies have been used to clone tumor-specific lymphocytes. 
The results, however, have been conflicting. For instance, Whiteside et al. (1986) found a lower frequency of proliferating T 
lymphocytes among tumor-infiltrating lymphocytes (TIL) than among peripheral blood lymphocytes (PBL) of the same patients. 
They measured frequencies of proliferating T lymphocytes by limiting dilution in a microculture system containing interleukin-2 
(IL-2), phytohemagglutinin (PHA) and allogeneic feeder cells. 
In contrast, Vose (1982) reported that TIL had a higher frequency of proliferating T lymphocytes than PBL from the same 
patient. He measured frequencies of proliferating T lymphocytes by limiting dilution in the presence of optimal concentrations 
of lectin-free medium containing IL-2 and autologous PBL as feeder cells. As yet, it is not clear whether such putative 
tumor-specijic CTL comprise CD4 + (helperlinducer) or CD8 + (suppressorlcytotoxic) cells. 
In this study we tested whether autologous tumor cells could induce responses of CD4 + andlor CD8 -+ lymphocytes, To this 
purpose PBL were cultured in a mixed lymphocyte-tumor-culture (MLTC), i.e. with or without autologous tumor cells (isolated 
from ascites or pleura) for I week, followed by another week of culture in the presence of IL-2 to select for tumor-activated 
lymphocytes. Finally, the tumor-activated lymphocytes were expanded in a lymphocyte-speciJic culture system containing PHA, 
IL-2 and allogeneic feeder cells (van de Griend et al., 1985), in order to obtain sufficient cell numbers toperform functional and 
phenotypic analysis. After 2 weeks of culture, activation markers such as proliferative activity, the presence of CD25 receptors 
and cytotoxic activity of PBL stimulated with autologous tumor cells in vitro were examined. 
Cytotoxicity by MLTC-activated PBL of cancer patients was found against fresh autologous andlor allogeneic tumor cells 
derived from lung, ovarian, mammary and endometrial carcinomas. However, in the absence of PHA, cytotoxic activities 
TABLE I - ELEVATED PERCENTAGES OF CDZ5+ LYMPHOCYTES IN FRESH PBL OF CANCER PATIENTS 
% CD25 
lvmoh. Chemotherapy 
Patient Type Malignancy Isolated 
number of tumor made from 
1 Endometrial 
2 Endometrial' 
3 Ovarian 
4 Ovarian 
5 Ovarian 
6 Ovarian 
7 Ovarian 
8 Ovarian 
9 Ovarian 
10 ovarian 
11 Mammary 
12 Mammary 
13 Mammary 
14 Mammary 
15 Mammary 
16 Mammary 
17 Mesothelioma 
18 Gall-bladder 
19 N.D.4 
20 N.D. 
21 N.D. 
22 N.D. 
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Pap V 
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Pap II 
Ascites 
Ascites 
Ascites 
Ascites 
Pleura 
Ascites 
Ascites 
Ascites 
Ascites 
Ascites 
Ascites 
Ascites 
Pleura 
Pleura 
Pleura 
Pleura 
Ascites 
Ascites 
Ascites 
Pleura 
Ascites 
Ascites 
Yes 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
No 
No 
No 
Yes 
No 
Yes 
Yes 
17 
12 
29 
0 
10 
7 
3 
22 
24 
6 
8 
2 
14 
0 
22 
0 
6 
7 
0 
6 
11 
11 
~ 1 0 3  
'Including sarcomatous components.-*Pap I and Il = non-malignant cells were found in pleura or ascites; Pap III = observed 
cells were suspected of malignancy; Pap IV and V = malignant cells were found in pleura or a~cites.-~Median = 2.-4N.D. 
= not determined. 
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TABLE II - IN VITRO ACTIVATION OF CD4+ -ENRICHED LYMPHOCYTES BY 
AUTOLOGOUS TUMOR CELLS 
Fresh PBL 
CD3 CD4 CD8 CD16 CD25 
Days of culture Tumor 
after MLTC/IL-D cells percentage of positive cells 
0 - 50 33 17 8 0 
Absolute number of positive cells' X lo4 
14 - 207 263 4 21 263 
14 + 402 391 5 57 397 
'Absolute number of positive cells were calculated total number of cells per ml 
culture x percentage of positive cell~.-~CD4+ -enriched lymphocytes were obtained 
by labelling PBL with anti-CD8 MAbs. Positive and negative fractions were sepa- 
rated by a fluorescence-activated cell sorter. The negative fraction was used as 
CD4 + -enriched lymphocytes. CD4 +-enriched lymphocytes were stimulated in a 
MLTC and cultured for 1 week in IL-2, then for 2 more weeks in a lymphocyte- 
expansion system. 
decreased to very low levels (results not shown). Ferrini et al. (1985) reported having obtained cytotoxic tumor-specijic cloned 
lymphocytes. However, these clones were cultured in the presence of PHA and results obtained in the absence of PHA were not 
reported. 
Although cytotoxicity could not be induced in PBL by autologous tumor cells, our additional results indicate that the tumors 
used in this study were immunogenic. Fresh PBL of 9 out of 22 cancer patients showed augmented levels of CD25 + lymphocytes 
(11-29%), while fresh PBL from healthy individuals comprised 610% CD25 + lymphocytes (Table I ) .  This suggests that they 
were activated in vivo (possibly by the tumor cells). PBL from 4 of these cancer patients (3 with normal and I with an elevated 
level of CD25 + lymphocytes among fresh PBL) were cultured with and without autologous tumor cells, and the proliferative 
activity of CD4+ and CD8+ lymphocytes was subsequently determined. In all 4 cases, CD4+ lymphocytes responded to 
autologous tumor cells, as measured by enhanced proliferation in comparison to PBL cultured without autologous tumor cells, 
although the responses were of different strengths (data not shown). CD8+ lymphocytes were stimulated much less, or not at all. 
Moreover, when CD4 + -enriched lymphocytes were stimulated with autologous tumor cells, an increase in absolute numbers of 
CD4 + as well as CD25 + lymphocytes was observed in comparison to the CD4 + -enriched cells cultured without autologous 
tumor cells (Table II). In contrast, CD8 + -enriched lymphocytes, stimulated and cultured under the same conditions as 
CD4 + -enriched cells, did not proliferate. The absence of CD4 + lymphocytes during the first week of MLTC could explain the 
failure of CD8+ lymphocytes to proliferate. 
Yours sincerely, 
C. GRAVEKAMP, .  BONTENBAL, C.P.M. RONTELTAP, D.  VAN DUYVENBODE and R.L.H. BOLHUIS 
Department of Immunology, Dr Daniel den Hoed Cancer Center, Groene Hilledijk 301,3075 EA Rotterdam, The Netherlands. 
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